GP IIb/IIIa Antagonists
Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt ves...
Ausführliche Beschreibung
Autor*in: |
Kleiman, Neal S. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
1999 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Drugs in R & D - [S.l.] : Springer International, 1999, 1(1999), 5 vom: Mai, Seite 361-370 |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:1999 ; number:5 ; month:05 ; pages:361-370 |
Links: |
---|
DOI / URN: |
10.2165/00126839-199901050-00001 |
---|
Katalog-ID: |
SPR033286841 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR033286841 | ||
003 | DE-627 | ||
005 | 20230519191741.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s1999 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2165/00126839-199901050-00001 |2 doi | |
035 | |a (DE-627)SPR033286841 | ||
035 | |a (SPR)00126839-199901050-00001-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Kleiman, Neal S. |e verfasserin |4 aut | |
245 | 1 | 0 | |a GP IIb/IIIa Antagonists |
264 | 1 | |c 1999 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. | ||
650 | 4 | |a Percutaneous Coronary Intervention |7 (dpeaa)DE-He213 | |
650 | 4 | |a Adis International Limited |7 (dpeaa)DE-He213 | |
650 | 4 | |a Acute Coronary Syndrome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Unstable Angina |7 (dpeaa)DE-He213 | |
650 | 4 | |a Abciximab |7 (dpeaa)DE-He213 | |
773 | 0 | 8 | |i Enthalten in |t Drugs in R & D |d [S.l.] : Springer International, 1999 |g 1(1999), 5 vom: Mai, Seite 361-370 |w (DE-627)357171527 |w (DE-600)2094513-9 |x 1179-6901 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:1999 |g number:5 |g month:05 |g pages:361-370 |
856 | 4 | 0 | |u https://dx.doi.org/10.2165/00126839-199901050-00001 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2190 | ||
936 | b | k | |a 44.40 |q ASE |
951 | |a AR | ||
952 | |d 1 |j 1999 |e 5 |c 05 |h 361-370 |
author_variant |
n s k ns nsk |
---|---|
matchkey_str |
article:11796901:1999----::piiiatg |
hierarchy_sort_str |
1999 |
bklnumber |
44.40 |
publishDate |
1999 |
allfields |
10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370 |
spelling |
10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370 |
allfields_unstemmed |
10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370 |
allfieldsGer |
10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370 |
allfieldsSound |
10.2165/00126839-199901050-00001 doi (DE-627)SPR033286841 (SPR)00126839-199901050-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kleiman, Neal S. verfasserin aut GP IIb/IIIa Antagonists 1999 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 Enthalten in Drugs in R & D [S.l.] : Springer International, 1999 1(1999), 5 vom: Mai, Seite 361-370 (DE-627)357171527 (DE-600)2094513-9 1179-6901 nnns volume:1 year:1999 number:5 month:05 pages:361-370 https://dx.doi.org/10.2165/00126839-199901050-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 1 1999 5 05 361-370 |
language |
English |
source |
Enthalten in Drugs in R & D 1(1999), 5 vom: Mai, Seite 361-370 volume:1 year:1999 number:5 month:05 pages:361-370 |
sourceStr |
Enthalten in Drugs in R & D 1(1999), 5 vom: Mai, Seite 361-370 volume:1 year:1999 number:5 month:05 pages:361-370 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Percutaneous Coronary Intervention Adis International Limited Acute Coronary Syndrome Unstable Angina Abciximab |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Drugs in R & D |
authorswithroles_txt_mv |
Kleiman, Neal S. @@aut@@ |
publishDateDaySort_date |
1999-05-01T00:00:00Z |
hierarchy_top_id |
357171527 |
dewey-sort |
3610 |
id |
SPR033286841 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033286841</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191741.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00126839-199901050-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033286841</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00126839-199901050-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kleiman, Neal S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">GP IIb/IIIa Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous Coronary Intervention</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Coronary Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Unstable Angina</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abciximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs in R & D</subfield><subfield code="d">[S.l.] : Springer International, 1999</subfield><subfield code="g">1(1999), 5 vom: Mai, Seite 361-370</subfield><subfield code="w">(DE-627)357171527</subfield><subfield code="w">(DE-600)2094513-9</subfield><subfield code="x">1179-6901</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:5</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:361-370</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00126839-199901050-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1999</subfield><subfield code="e">5</subfield><subfield code="c">05</subfield><subfield code="h">361-370</subfield></datafield></record></collection>
|
author |
Kleiman, Neal S. |
spellingShingle |
Kleiman, Neal S. ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab GP IIb/IIIa Antagonists |
authorStr |
Kleiman, Neal S. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)357171527 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1179-6901 |
topic_title |
610 ASE 44.40 bkl GP IIb/IIIa Antagonists Percutaneous Coronary Intervention (dpeaa)DE-He213 Adis International Limited (dpeaa)DE-He213 Acute Coronary Syndrome (dpeaa)DE-He213 Unstable Angina (dpeaa)DE-He213 Abciximab (dpeaa)DE-He213 |
topic |
ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab |
topic_unstemmed |
ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab |
topic_browse |
ddc 610 bkl 44.40 misc Percutaneous Coronary Intervention misc Adis International Limited misc Acute Coronary Syndrome misc Unstable Angina misc Abciximab |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Drugs in R & D |
hierarchy_parent_id |
357171527 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Drugs in R & D |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)357171527 (DE-600)2094513-9 |
title |
GP IIb/IIIa Antagonists |
ctrlnum |
(DE-627)SPR033286841 (SPR)00126839-199901050-00001-e |
title_full |
GP IIb/IIIa Antagonists |
author_sort |
Kleiman, Neal S. |
journal |
Drugs in R & D |
journalStr |
Drugs in R & D |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
1999 |
contenttype_str_mv |
txt |
container_start_page |
361 |
author_browse |
Kleiman, Neal S. |
container_volume |
1 |
class |
610 ASE 44.40 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Kleiman, Neal S. |
doi_str_mv |
10.2165/00126839-199901050-00001 |
dewey-full |
610 |
title_sort |
gp iib/iiia antagonists |
title_auth |
GP IIb/IIIa Antagonists |
abstract |
Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. |
abstractGer |
Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. |
abstract_unstemmed |
Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_20 GBV_ILN_702 GBV_ILN_2190 |
container_issue |
5 |
title_short |
GP IIb/IIIa Antagonists |
url |
https://dx.doi.org/10.2165/00126839-199901050-00001 |
remote_bool |
true |
ppnlink |
357171527 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.2165/00126839-199901050-00001 |
up_date |
2024-07-03T17:44:28.297Z |
_version_ |
1803580780891340800 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033286841</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191741.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1999 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00126839-199901050-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033286841</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00126839-199901050-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kleiman, Neal S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">GP IIb/IIIa Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1999</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Percutaneous Coronary Intervention</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute Coronary Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Unstable Angina</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Abciximab</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs in R & D</subfield><subfield code="d">[S.l.] : Springer International, 1999</subfield><subfield code="g">1(1999), 5 vom: Mai, Seite 361-370</subfield><subfield code="w">(DE-627)357171527</subfield><subfield code="w">(DE-600)2094513-9</subfield><subfield code="x">1179-6901</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1999</subfield><subfield code="g">number:5</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:361-370</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00126839-199901050-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1999</subfield><subfield code="e">5</subfield><subfield code="c">05</subfield><subfield code="h">361-370</subfield></datafield></record></collection>
|
score |
7.400346 |